Loading...
Market
Which competitor will launch a new colorectal cancer screening test by end of 2025?
2
Resolution / Starting Odds
Guardant Health • 25%
Roche • 25%
Illumina • 25%
Other • 25%
Announcements from major diagnostic companies
Story
Exact Sciences' ($EXAS) Stock Rises as FDA Approves Cologuard Plus, Setting New Benchmark in Colorectal Cancer Screening
Oct 4, 2024, 04:49 PM
Exact Sciences (NASDAQ: EXAS) announced that on Friday it received approval from the U.S. Food and Drug Administration (FDA) for its Cologuard Plus™ test, an improved stool-based screening assay for colorectal cancer. The Cologuard Plus test is a next-generation multitarget stool DNA test designed for non-invasive colorectal cancer screening in adults aged 45 and older who are at average risk for colorectal cancer (CRC). The FDA approval sets a new benchmark in non-invasive colorectal cancer screening, providing an improved option for early detection of colon cancer. Following the announcement, Exact Sciences' stock price rose.
View original story
Similar markets
Guardant Health becomes the market leader • 25%
Guardant Health is among the top 3 • 25%
Guardant Health remains in the top 5 • 25%
Guardant Health does not make it to the top 5 • 25%
Guardant Health's Shield • 25%
Exact Sciences' Cologuard • 25%
Epigenomics' Epi proColon • 25%
Other • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Guardant Reveal • 25%
Guardant360 • 25%
GuardantOMNI • 25%
None • 25%
Pfizer • 25%
Merck • 25%
Roche • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
AstraZeneca • 25%
Other • 25%
Positive results for Shield • 25%
Positive results for Reveal • 25%
Positive results for Guardant360 • 25%
No positive results • 25%
Manufacturer A • 25%
Manufacturer B • 25%
Manufacturer C • 25%
Other • 25%
Market share increases • 25%
Market share remains the same • 25%
Market share decreases • 25%
Foresight exits cancer-detection market • 25%
Yes • 50%
No • 50%
Manufacturer A has largest share • 25%
Manufacturer B has largest share • 25%
Manufacturer C has largest share • 25%
Manufacturer D or others have largest share • 25%
Bristol-Myers Squibb • 25%
Merck & Co. • 25%
Pfizer • 25%
Other • 25%